Global Health Investment Fund (GHIF)

Name

Global Health Investment Fund (GHIF)

Legal name

Global Health Investment Corporation

Website

https://ghif.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Impact Investment Fund

NAICS

Finance and Insurance (52), Open-End Investment Funds (52591)

SIC

Investment Advice (6282), International Affairs (9721)

akta.pro primary industry

Global Health Financing Mechanisms (HLAJAKAC)

akta.pro secondary industries

International & Global Public Health Aid Administration (Government Donors) (HLAJALAO), Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF), Immunization & Vaccine Access Partnerships (Global Vaccine Alliances) (HLAJAOAF), Health Research Funding Agencies (Public/Quasi-Public) (HLAJALAB)

Keywords

• Impact investment fund
• Global health financing
• Healthcare venture capital
• Social impact investing
• Biomedical investment

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Core offering

Global Health Investment Corporation (GHIC) operates as a nonprofit impact investment organization that finances late-stage development of new drugs, vaccines, diagnostics, and devices for public health challenges. It manages the $108 million Global Health Investment Fund (GHIF) targeting infectious diseases in low- and middle-income countries and a Global Health Security Portfolio in partnership with BARDA supporting pandemic preparedness technologies.

Product overview

Global Health Investment Corporation (GHIC) operates two distinct investment products: the Global Health Investment Fund (GHIF), a $108 million social impact fund focused on infectious disease diagnostics, devices, vaccines, and therapeutics for low- and middle-income countries; and the Global Health Security Portfolio, a BARDA-partnered venture capital program targeting pandemic preparedness and public health emergency technologies. Both products are investment vehicles rather than technology products, focusing on funding and accelerating healthcare innovation rather than offering a unified software platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Health Investment Fund (GHIF) A $108 million social impact fund that invests in companies developing clinical diagnostics, devices, vaccines, and therapeutics for infectious diseases such as HIV/AIDS, malaria, tuberculosis, and cholera that disproportionately affect low- and middle-income countries. Portfolio companies have commercialized more than a dozen products delivered to over 500 million people. Investors and partners include foundations, corporations, nonprofits, and governmental agencies.
• Global Health Security Portfolio A venture capital investment portfolio operated in partnership with the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services. It supports development and commercialization of technologies that respond to or prevent public health emergencies, pandemics, and other global health security threats.

Quantifiable outcome

• 500+ million people reached with health interventions
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core and supporting.

• BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development PartnerPartnership within the Administration for Strategic Preparedness and Response at U.S. Department of Health and Human Services. BARDA and GHIC collaborate on venture capital investments to support development and commercialization of technologies responding to public health emergencies, pandemics, and global health security threats. Quote from BARDA Director Gary Disbrow: 'Pathogens and health security threats constantly evolve. To combat them, we need to tap into the most novel and impactful ideas in the entrepreneurial community.'
• MITREsupportingStrategic or Co-development PartnerNonprofit organization operating federally funded research and development centers, supporting public health security initiatives.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Adjuvant Capital: Life sciences impact investment fund backed by the Gates Foundation and other global health LPs that finances late-stage development of vaccines, therapeutics, and diagnostics for LMIC markets - directly comparable in mandate, capital structure, and target diseases.
• Global Health Investment Corporation (GHIC) - BARDA DRIVe partnership vehicles: The DRIVe (Division of Research, Innovation, and Ventures) program at BARDA is a co-investment partner and adjacent funder in the same health-security venture thesis, investing in companies developing countermeasures for pandemic and public health threats.
• Acumen: Impact investment fund with a healthcare-focused arm (Acumen America and global health portfolio) that invests in early- and growth-stage companies serving low-income populations; comparable in nonprofit impact-investor model, LP base, and LMIC focus.
• LeapFrog Investments: Profit-with-purpose investment firm targeting financial services and healthcare in emerging markets; comparable in scale, return-and-impact thesis, and emerging-market LP/investor base.

Broad incumbents

• Gavi, the Vaccine Alliance: Public-private global health partnership that finances vaccine procurement and introduction in LMICs at much larger scale; comparable in mission to expand access to vaccines for underserved populations, though Gavi is a procurement/financing mechanism rather than a venture investor.
• Global Fund to Fight AIDS, Tuberculosis and Malaria: The world's largest multilateral financing institution for HIV/AIDS, TB, and malaria programs in LMICs; directly comparable disease focus to GHIF's portfolio and a likely downstream procurement partner for portfolio products.
• Wellcome Trust: Major charitable foundation that invests directly and via venture funds in global health R&D, including infectious disease therapeutics and vaccines; comparable as both an LP and as a co-investor in similar life sciences companies.
• PATH: Global health nonprofit that develops and delivers vaccines, drugs, and diagnostics for LMICs, often partnering with product developers and funders; comparable in mission and overlapping with several GHIF portfolio company therapeutic areas.
• International Finance Corporation (IFC) Healthcare Group: World Bank Group's private-sector arm and an existing GHIC partner/investor; IFC makes large equity, debt, and fund commitments in health companies and funds serving emerging markets, often co-investing in the same opportunities.

Emerging players

• Medicines Development for Global Health: Nonprofit pharmaceutical company developing and distributing neglected-disease treatments for LMICs; comparable in nonprofit global-health product development model though operating as a product developer rather than a fund.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments17 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Health Investment Fund (GHIF)